


**WHAT IS CLAIMED:**

1. A method of treating pain comprising administering to a subject a pharmaceutical composition comprising an effective amount of a compound of Formula I, a tautomer, or a  
 5 pharmaceutically-acceptable salt, -hydrate, or -solvate thereof:

Formula I



10

wherein  $R_a$  and  $R_b$  are each independently selected from the group consisting of: hydrogen, saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aralkyl, aryl, and saturated or unsaturated  $C_{2-6}$  heterocycle; or

15

$R_a$  and  $R_b$  are optionally taken together to form a ring of 3 to 7 members, with or without substitution, and with or without heteroatoms in place of ring carbon atoms;

$R_c$  and  $R_c'$  are independently selected from the group consisting of: H, OR, saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aralkyl, aryl, saturated or unsaturated heterocycle, and  $-C(G)\Sigma$ ; wherein  $G = O, S$  or  $NR_d$ ; and  $\Sigma = L, R_d, OR_d$ , or  $N(R_d)_2$ ; except that  $-NR_cR_c'$  cannot be  $-N(OR)_2$ ; and  $OR_d$  cannot be  $-OH$ ;

20

each  $R_d$  is independently selected from the group consisting of: H, saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aralkyl, aryl, heteroaryl, and saturated or unsaturated  $C_{2-6}$  heterocycle; or

two R<sub>d</sub> groups are optionally taken together to form a ring of 4 to 7 members, with or without unsaturation and with or without heteroatoms in place of ring-carbon units; or

one R<sub>d</sub> and one of R<sub>c</sub> or R<sub>c</sub>' are optionally taken together to form a ring of 4 to 7 members, with or without unsaturation and with or without heteroatoms in place of ring-carbon units;

- 5 R is selected from the group consisting of: H, saturated or unsaturated C<sub>1-8</sub> alkyl, saturated or unsaturated C<sub>3-7</sub> cycloalkyl, aryl, aralkyl, heteroaryl, and saturated or unsaturated C<sub>2-6</sub> heterocycle;

L is selected from the group consisting of: H, -CF<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, saturated or unsaturated C<sub>1-8</sub> alkyl, saturated or unsaturated C<sub>3-7</sub> cycloalkyl, aryl, aralkyl, heteroaryl, saturated or

- 10 unsaturated C<sub>2-6</sub> heterocycle, saturated or unsaturated C<sub>1-6</sub> alkoxy, aralkoxy, aryloxy, N,N-disubstituted-amino, N-substituted amino, and unsubstituted-amino;

when L is N-substituted-amino, or N,N-disubstituted-amino, each substituent of said amino group of L is selected from the group consisting of: C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, aryl, aralkyl, heteroaryl, and saturated or unsaturated C<sub>2-6</sub> heterocycle;

- 15 when L is N,N-disubstituted-amino, the two substituents independently selected from the group above are optionally taken together to form a ring of 3 to 7 members, wherein said formed ring thereon bears the remaining features of said selected substituents before said ring formation;

R<sub>e</sub> = O or absent;

- 20 R<sub>f</sub> = H, halogen, saturated or unsaturated C<sub>1-8</sub> alkyl, saturated or unsaturated C<sub>3-7</sub> cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated C<sub>2-6</sub> heterocycle, -OH, saturated or unsaturated C<sub>1-6</sub> alkoxy, aryloxy, -SH, C<sub>1-6</sub> thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], amino, -N-substituted amino, or N,N-disubstituted amino; wherein each said substituent on said N-substituted-amino-group, or N,N-disubstituted-amino-group of R<sub>f</sub> is independently  
25 selected from the group consisting of: C<sub>1-8</sub> alkyl, C<sub>3-7</sub> cycloalkyl, aryl, aralkyl, heteroaryl, C<sub>2-6</sub> heterocycle, -[(CO)R] and -[(CO)-NRR]; wherein each R is independently as defined above;  
or

when R<sub>f</sub> is -[(CO)NRR], -[NH(CO)NRR], -[N(C<sub>1-8</sub> alkyl)(CO)NRR], -[N(aryl)(CO)NRR], or [N(aralkyl)(CO)NRR], the R groups of a said -NRR unit in R<sub>f</sub> are optionally taken together

- 30 such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units;

J = N or C, with the proviso that when J = N, then R<sub>g</sub> is absent;

when  $J = C$ ,  $R_g$  is selected from the group consisting of: -H, halogen, saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aralkyl, aryl, -OH, saturated or unsaturated  $C_{1-6}$  alkoxy, aryloxy, -SH,  $C_{1-6}$  thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], and -NRR; wherein each R is independently as defined above; or

- 5 when  $R_g$  is -[(CO)NRR] or -NRR, the R groups of said -NRR unit in  $R_g$  can be taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units;

A and B are each independently selected from the group consisting of: - $C_{1-3}$  alkylene-, -CF<sub>2</sub>-, and -(CO)-; wherein each said - $C_{1-3}$  alkylene- unit of A and B independently is saturated or  
 10 unsaturated, and each carbon of a - $C_{1-3}$  alkylene- unit of B independently is substituted with 0 to 2 fluorine groups, 0 to 1 methyl groups, 0 to 2 -[(CO)OR] groups, and 0 to 1 -(OR) groups; or

B is absent; or

any one-carbon-unit within either or both of said  $C_{1-3}$  alkylene units of A and B is substituted  
 15 with a heteroatom-containing-unit selected from the group: -O-, -S-, -NR-, -[NR(CO)]-, or -N[(CO)L]-, where each R and L is independently as defined above; provided that (a) fewer than three said heteroatom-containing-unit for one-carbon-unit substitutions on the -A-B- chain are made, (b) no -S-S- or -O-O- bonds are formed in the X-A-B- chain by said substitution or substitutions of a heteroatom-containing-unit for a one-  
 20 carbon-unit on the -A-B- chain, and (c) no said heteroatom substitution is made such that the said replacement heteroatom connects directly to the tetrahydrofuran ring shown in Formula I;  $X = -OR$ , -SR, -S(O)L, -S(O<sub>2</sub>)L, -SO<sub>3</sub>H, -S(O<sub>2</sub>)NRR, -S(O<sub>2</sub>)NR(CO)L, -NRR, -NR(CO)L, -N[(CO)L]<sub>2</sub>, -NR(SO<sub>2</sub>)L, -NR(CO)NR(SO<sub>2</sub>)L, -NR(SO<sub>2</sub>)NRR, or -NR(SO<sub>2</sub>)NR(CO)L; wherein each R and L is independently as defined above;


25 wherein the R groups of a -NRR unit in X are optionally taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units; with the proviso that no compound in Formula I contains: a halogen-group, hydroxy-group, sulfhydryl-group, or amino-group attached to an sp<sup>3</sup>-hybridized-carbon atom that is bonded directly to a heteroatom selected from the group consisting of O, S and N;  
 30 the first exception to this proviso is: compounds in which the said sp<sup>3</sup>-hybridized-carbon atom is bonded directly to: 1) a sulfur atom which is part of a-[S(O)]-group, or a-[S(O<sub>2</sub>)]-group, and also to: 2) one or more halogen groups;

the second exception to this proviso is the C-1' position of the furanose of compounds of Formula I wherein the  $sp^3$ -hybridized carbon atom at the 1'-position is attached to: 1) the oxygen atom of the furanose ring and to: 2) the nitrogen atom of the adenine or 8-azaadenine moiety; or

5

X is a group as provided in Formula II:

Formula II



10

wherein:

$n = 1$  to  $4$ , inclusive;

Y, Z and Z' are independently selected from  $-CRR_f$ -,  $-NR$ -,  $-[N(CO)L]$ -,  $-O$ - and  $-S$ -; or the said  $-Y-Z'$ -unit, taken together, can be selected to be a  $-N=N$ - unit or a  $-CR=CR_f$  unit; or any- $(Z)_2$ -unit or subunit of  $-(Z)_n$  can be selected to be a  $-CR=CR_f$  unit; and

15

with the provisos that the ring shown in Formula II contains no more than three heteroatoms, and that the shown pendant  $-CO_2R$  unit in Formula II is a substituent on the ring described in Formula II, and that the ring of Formula II contains no halogen-group, hydroxy-group, sulfhydryl-group, or amino-group attached to an  $sp^3$ -hybridized-carbon atom that is bonded directly to a heteroatom selected from the group consisting of O, S, and N.

20

2. The method according to Claim 1, wherein said compound is selected from the group consisting of: 3-{6-[6-(3-Ethyl-1-phenyl-ureido)-purin-9-yl]-2,2-dimethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-isoxazole-5-carboxylic acid; 3-(6-{6-[3-Ethyl-1-(5-methyl-furan-2-ylmethyl)-ureido]-purin-9-yl}-2,2-dimethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy)-isoxazole-5-carboxylic acid; 3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-isoxazole-5-carboxylic


25

acid; 3-{2,2-Dimethyl-6-[6-(3-phenyl-1-propyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-isoxazole-5-carboxylic acid; 5-Amino-2-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-N-hydroxy-benzamide; 6-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinamide; 1-{9-[6-(3-Hydroxy-pyridin-2-yloxymethyl)-2,2-dimethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl]-9H-purin-6-yl}-3-phenyl-urea; 3-({2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-amino)-benzoic acid; 2-({2-Benzyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-amino)-3-hydroxy-propionic acid; N-{2-Benzyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-methanesulfonamide; 1-[9-(2-Benzyl-6-ureidomethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl)-9H-purin-6-yl]-3-phenyl-urea methylsulfonamide; 3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl}-acrylic acid methyl ester; 3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl}-propionic acid methyl ester; 3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl}-propionic acid; and 3-(3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl}-propionylamino)-benzoic acid.

3. A method of treating pain comprising administering to a subject a pharmaceutical composition comprising an effective amount of a compound of Formula III, a tautomer, or a pharmaceutically-acceptable salt, -hydrate, or -solvate thereof:

5

Formula III



- 10 wherein  $R_a$ ,  $R_b$ ,  $R_c$ ,  $R_c'$ ,  $\Sigma$ ,  $R$ ,  $L$ ,  $R_d$ ,  $R_e$ ,  $R_f$ ,  $J$ ,  $R_g$  are as defined in Formula I of Claim 1;  $X_1$  is selected from the group consisting of: N and C-M; and M is independently selected from the group consisting of: -H, halogen,  $CF_3$ , saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated  $C_{2-6}$  heterocycle, -OH,  $C_{1-6}$  alkoxy, aralkoxy, aryloxy, -SH,  $C_{1-6}$  thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], amino, -N-substituted amino, and N,N-disubstituted amino; wherein each said substituent on said amino of M is independently selected from the group consisting of: saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated  $C_{2-6}$  heterocycle, -[(CO)R], -[(CO)O-( $C_{1-8}$  alkyl)], and -[(CO)-NRR]; and when M is -[(CO)NRR], -
- 15 [NH(CO)NRR], -[N( $C_{1-8}$  alkyl)(CO)NRR], -[N(aryl)(CO)NRR], or -[N(aralkyl)(CO)NRR], the R groups of any said -NRR unit in M are optionally taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units.
- 20

4. The method according to Claim 3, wherein said compound is selected from the group consisting of: 5-Amino-2-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-benzoic acid; 4-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-isophthalic acid; 4-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-benzoic acid; 6-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 5-Chloro-6-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 6-Chloro-2-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-5-fluoro-nicotinic acid; 6-Chloro-2-{2,2-dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-5-fluoro-nicotinic acid; 2-[6-[6-(3-Phenyl-ureido)-purin-9-yl]-2-(2-trifluoromethyl-phenyl)-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Phenyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Biphenyl-3-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Naphthalen-2-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Benzo[*b*]thiophen-3-yl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Hexyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxo-spiroindan-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenylethynyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-(2-Bromo-phenyl)-6-[6-(3-ethyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-phenethyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2,2-(3,4-Dihydro-1H-naphthalen)-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-p-tolyl-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-Biphenyl-4-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-


*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; 2-{2-(4-Acetylamino-phenyl)-6-[6-(3-cyclopentyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid; and 2-{2-*tert*-Butyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-ylmethoxy}-nicotinic acid.

5

5. A method of treating pain comprising administering to a subject a pharmaceutical composition comprising an effective amount of a compound of Formula IV, a tautomer, or a pharmaceutically-acceptable salt, -hydrate, or -solvate thereof:

Formula IV

10



wherein  $R_a$ ,  $R_b$ ,  $R_c$ ,  $R_c'$ ,  $\Sigma$ ,  $R$ ,  $L$ ,  $R_d$ ,  $R_e$ ,  $R_f$ ,  $J$ ,  $R_g$  are as defined in Formula I of Claim I;

$M'$  is selected from the group consisting of: -H, halogen,  $CF_3$ , saturated or unsaturated  $C_{1-8}$

15 alkyl, saturated or unsaturated  $C_{3-7}$  cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated  $C_{2-6}$  heterocycle, -OH,  $C_{1-6}$  alkoxy, aralkoxy, aryloxy, -SH,  $C_{1-6}$  thioalkyl, thioaryl, -[(CO)OR], -[(CO)NRR], amino, -N-substituted amino, and N,N-disubstituted amino; wherein each said substituent on said amino of M is independently selected from the group consisting of: saturated or unsaturated  $C_{1-8}$  alkyl, saturated or unsaturated  $C_{3-7}$

20 cycloalkyl, aryl, aralkyl, heteroaryl, saturated or unsaturated  $C_{2-6}$  heterocycle, -[(CO)R], -[(CO)O-( $C_{1-8}$  alkyl)], and -[(CO)-NRR]; and when  $M'$  is -[(CO)NRR], -[NH(CO)NRR], -[N( $C_{1-8}$  alkyl)(CO)NRR], -[N(aryl)(CO)NRR], or -[N(aralkyl)(CO)NRR], the R groups of




any said -NRR unit in M' are optionally taken together such that a ring of 3 to 7 members is formed, with or without heteroatoms in place of the ring-carbon units;  
 the M' and -CO<sub>2</sub>R groups are independently attached to any carbon of the pyrrolidine ring;  
 and M' is not a halogen, hydroxy, sulfhydryl, or amino group when M' is attached to a carbon  
 5 that is bonded to the pyrrolidine nitrogen atom at the alpha position.

6. The method according to Claim 5, wherein said compound is selected from the group consisting of: 1-{2-Phenyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Phenyl-6-[6-(3-phenyl-  
 10 ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Benzyl-6-[6-(3-ethyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-(2-Phenyl-6-{6-[3-(2-phenyl-cyclopropyl)-ureido]-  
 purin-9-yl}-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl)-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Benzyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-  
 15 carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Benzo[*b*]thiophen-3-yl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{2-Benzyl-6-[6-(3-hexyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-  
 pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Ethyl-ureido)-purin-9-yl]-2-naphthalen-2-yl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-  
 20 Hexyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; 1-{6-[6-(3-Cyclopentyl-ureido)-purin-9-yl]-2-phenyl-tetrahydro-furo[3,4-*d*][1,3]dioxole-4-carbonyl}-pyrrolidine-2-carboxylic acid; and 1-(3-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-*d*][1,3]dioxol-4-yl}-  
 propionyl)-pyrrolidine-2-carboxylic acid.


25

7. A method of treating pain comprising administering to a subject a pharmaceutical composition comprising an effective amount of a compound of Formulae V-XI, a tautomer, or a pharmaceutically-acceptable salt, -hydrate, or -solvate thereof, in which R, R<sub>a</sub>, R<sub>b</sub>, J and R<sub>g</sub>, are defined as for Formula I in Claim 1, and n is 1-4:

Formula V




Formula VI




5

Formula VII




10

Formula VIII




5

Formula IX




10

Formula X



5

Formula XI



10

8. The method according to any one of Claims 1-7, wherein said pain is traumatic pain, neuropathic pain, organ pain, or pain associated with diseases.

5 9. The method according to Claim 8, wherein said traumatic pain is pain resulting from injury, burn, post-surgical pain or inflammatory pain.

10. The method according to Claim 8, wherein said organ pain is ocular, corneal, bone, heart, skin, visceral, joint, dental or muscle pain.

10 11. The method according to Claim 8, wherein said diseases are cancer, AIDS, arthritis, herpes, sickle cell anemia or migraine.

12. The method according to any one of Claims 1-7, wherein said pharmaceutical composition is administered topically to said subject.

15

13. The method according to any one of Claims 1-7, wherein said pharmaceutical composition is administered via injection to said subject.

14. The method according to any one of Claims 1-7, wherein said pharmaceutical composition is administered orally to said subject.

20

15. The method according to any one of Claims 1-7, wherein said pharmaceutical composition is administered by intranasal administration to said subject.

25 16. The method according to any one of Claims 1-7, wherein said pharmaceutical composition is administered to said subject in an inhaleable form.